Phase II study of vindesine in patients with metastatic breast cancer

M. A. Cobleigh, S. D. Williams, Lawrence Einhorn

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Twenty-six patients with far-advanced, refractory breast cancer were treated iv with vindesine (DVA) at a dose of 3 mg/m2/week. In 21 evaluable patients there were six partial remissions. Four patients who did not respond after at least four doses of intermittent DVA received continuous-infusion DVA at a dose of 1.5 mg/m2/day x 2 every other week; none responded. Five of the six responders had had disease progression on other vinca alkaloids. Leukopenia and neuromuscular toxicity were dose-limiting.

Original languageEnglish (US)
Pages (from-to)659-663
Number of pages5
JournalCancer Treatment Reports
Volume65
Issue number7-8
StatePublished - 1981
Externally publishedYes

Fingerprint

Vindesine
Breast Neoplasms
Vinca Alkaloids
Leukopenia
Disease Progression

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Phase II study of vindesine in patients with metastatic breast cancer. / Cobleigh, M. A.; Williams, S. D.; Einhorn, Lawrence.

In: Cancer Treatment Reports, Vol. 65, No. 7-8, 1981, p. 659-663.

Research output: Contribution to journalArticle

Cobleigh, M. A. ; Williams, S. D. ; Einhorn, Lawrence. / Phase II study of vindesine in patients with metastatic breast cancer. In: Cancer Treatment Reports. 1981 ; Vol. 65, No. 7-8. pp. 659-663.
@article{ed3c1a8b41364bc3aeb6841da8f61ce9,
title = "Phase II study of vindesine in patients with metastatic breast cancer",
abstract = "Twenty-six patients with far-advanced, refractory breast cancer were treated iv with vindesine (DVA) at a dose of 3 mg/m2/week. In 21 evaluable patients there were six partial remissions. Four patients who did not respond after at least four doses of intermittent DVA received continuous-infusion DVA at a dose of 1.5 mg/m2/day x 2 every other week; none responded. Five of the six responders had had disease progression on other vinca alkaloids. Leukopenia and neuromuscular toxicity were dose-limiting.",
author = "Cobleigh, {M. A.} and Williams, {S. D.} and Lawrence Einhorn",
year = "1981",
language = "English (US)",
volume = "65",
pages = "659--663",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "7-8",

}

TY - JOUR

T1 - Phase II study of vindesine in patients with metastatic breast cancer

AU - Cobleigh, M. A.

AU - Williams, S. D.

AU - Einhorn, Lawrence

PY - 1981

Y1 - 1981

N2 - Twenty-six patients with far-advanced, refractory breast cancer were treated iv with vindesine (DVA) at a dose of 3 mg/m2/week. In 21 evaluable patients there were six partial remissions. Four patients who did not respond after at least four doses of intermittent DVA received continuous-infusion DVA at a dose of 1.5 mg/m2/day x 2 every other week; none responded. Five of the six responders had had disease progression on other vinca alkaloids. Leukopenia and neuromuscular toxicity were dose-limiting.

AB - Twenty-six patients with far-advanced, refractory breast cancer were treated iv with vindesine (DVA) at a dose of 3 mg/m2/week. In 21 evaluable patients there were six partial remissions. Four patients who did not respond after at least four doses of intermittent DVA received continuous-infusion DVA at a dose of 1.5 mg/m2/day x 2 every other week; none responded. Five of the six responders had had disease progression on other vinca alkaloids. Leukopenia and neuromuscular toxicity were dose-limiting.

UR - http://www.scopus.com/inward/record.url?scp=0019495693&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019495693&partnerID=8YFLogxK

M3 - Article

C2 - 7248983

AN - SCOPUS:0019495693

VL - 65

SP - 659

EP - 663

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 7-8

ER -